Want to see JP:206A full AI Analyst Report?
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥279.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)2.26M
Market Cap
¥5.32B
Enterprise Value¥3.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.60
Shares Outstanding36,964,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers refinancing and interest risks, giving management flexibility to allocate cash to R&D, partnerships or pivots without fixed interest burdens. For a biotech with long development cycles this reduces solvency risk over the next few quarters.
Strong Revenue GrowthSustained, sharp top-line growth across 2024–2025 indicates emerging commercial traction or successful collaborations. A growing revenue base can support operating leverage, help absorb fixed R&D costs and create a path to margin improvement as programs scale over multiple quarters.
Proprietary Discovery TechnologyProprietary discovery capabilities and a focus on protein–protein interactions create a technical moat and differentiated pipeline focus. This durable scientific IP basis supports long-term licensing, partnerships and value capture beyond short-term market moves.
Bears Say
Persistent UnprofitabilityRecurring, sizable negative EBIT and net losses across 2023–2025 signal the business is not yet operationally profitable. Persistent losses elevate reliance on external capital, increase dilution risk and heighten execution pressure for clinical and commercial milestones over the medium term.
Deteriorating Cash GenerationWorsening operating cash flow and consistently negative free cash flow (except 2022) indicate accelerating cash burn and shrinking runway. This structural cash generation weakness can force equity raises, program cuts or slower development timelines, reducing strategic optionality.
Negative ROE And Volatile EquityStrongly negative ROE and volatile shareholders' equity reflect poor capital efficiency and likely financing activity. Over time this undermines shareholder value creation, complicates capital allocation and can impair investor confidence ahead of necessary fundraising rounds.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥125.00 and its highest was ¥279.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥5.32B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
PRISM BioLab Co. LTD’s upcoming earnings report date is Aug 14, 2026 which is in 41 days.
How were PRISM BioLab Co. LTD’s earnings last quarter?
PRISM BioLab Co. LTD released its earnings results on May 14, 2026. The company reported -¥8.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥8.6.
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,964,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
PRISM BioLab Co. LTD reported an EPS of -¥8.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM Pharma Co., Ltd. is a pharmaceutical enterprise dedicated to identifying and advancing small molecule compounds. Its core mission involves modulating protein-protein interactions. The company leverages a proprietary protein secondary structure mimetic library to regulate interactions between proteins within cells. A key product in its development pipeline is PRI-724, an anti-cancer CP/Catenin inhibitor. This drug targets both mature cancer cells and cancer stem cells, inducing them to transition from uncontrolled proliferation to differentiation. Hiroyuki Kouji founded the organization on November 2, 2006, and it is headquartered in Fujisawa, Japan.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―